Profound Medical Corp.

TORONTO – October 14, 2026 -- Patients treated with whole-gland TULSA were more than twice as likely to preserve both erectile function and pad-free continence at six months as those who had robotic radical prostatectomy (risk ratio 2.1; p=0.004), according to CAPTAIN trial data. Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) presented the results among five abstracts at the 15th Interventional MRI Symposium in Boston.

CAPTAIN trial shows whole-gland TULSA cut complication hospitalizations to 0.7% versus 6.3% for robotic surgery

CAPTAIN is the first fully enrolled, multicenter randomized controlled trial to compare the TULSA Procedure directly with robotic radical prostatectomy in localized intermediate-risk prostate cancer. Whole-gland TULSA also showed statistically superior preservation of flaccid penile length at one month.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will report its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Management hosts call at 4:30 p.m. ET on results day

The interventional MRI (iMRI) company will hold a conference call at 4:30 p.m. ET on August 6 to review the quarter's results and discuss business developments in the period. Investors must register in advance for the live call.

Two MRI-guided platforms drive the commercial portfolio

Profound markets TULSA-PRO, which is FDA-cleared in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. The system is also cleared in Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the UAE.

Toronto – October 12, 2026 -- Men treated with whole-gland TULSA Procedure showed no median change in penile length at one month, compared with a median 0.65 cm reduction after robotic radical prostatectomy (RP), according to new data from the Level 1 CAPTAIN randomized controlled trial, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced.

Mixed-effects model shows 0.42 cm between-arm difference

The between-arm difference in change in penile length, estimated from a mixed-effects model, was 0.42 cm (p<0.001), which Profound describes as statistically significant. Xiaosong Meng, MD, PhD, Assistant Professor in the Department of Urology at UT Southwestern Medical Center, presented the results at the Society of Robotic Surgery Annual Meeting in Fort Lauderdale, Florida.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) cut its second-quarter 2026 net loss 39% to about $9.5 million, or $0.26 per share, from $15.7 million, or $0.52 per share, a year earlier. Operating expenses fell 16% to about $13.0 million, and the company reiterated its full-year revenue guidance of about $25.0 million.

Shipment delay pushes $3.1 million of TULSA revenue into July

Q2 revenue was about $2.5 million, up 12% year over year. Recurring non-capital revenue from single-use devices and extended-warranty services contributed $1.6 million, and capital equipment sales added $871,000.

About $3.1 million of TULSA product shipments expected in the final week of June went out in July and will be recognized in Q3. Excluding the delay, Q2 revenue would have been about $5.6 million, or 153% growth. The company attributes the slip to a logistics issue, not weaker demand, and says the issue is resolved.

Toronto – – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) replaced its chief financial officer effective immediately, promoting Corporate Controller Matthew Sobczyk to Interim CFO after Rashed Dewan stepped down from the role.

Sobczyk, a 2020 hire, takes over the finance function

Sobczyk first joined the interventional MRI (iMRI) company in 2020 and moves up from Corporate Controller. The company did not name a permanent successor or give a timeline for a CFO search.

Dewan stays on a short-term consulting contract

Dewan will remain with Profound under a short-term consulting contract to support the handover. CEO and Chairman Arun Menawat thanked him for his years of service and his contributions to the company.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has introduced new Treatment Delivery Console (TDC) software that it says provides a roadmap for surgeons to perform up to six TULSA Procedures per system per day, up from a reported maximum of four among a few physicians today.

Software rolls out across the TULSA-PRO installed base

The update is being deployed across Profound's TULSA-PRO installed base. It builds on earlier TULSA-AI modules aimed at raising procedural efficiency, improving physician experience and reducing planning complexity.

The release adds two feature sets. The first is real-time interventional MRI (iMRI) control. The second is a package of physician-requested improvements to the user interface and hardware control. Profound says both are designed to further increase TULSA Procedure efficiency and support regional ablation of tissue for a variety of prostate indications.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has appointed Richard Fabian, a medical imaging executive with more than 29 years of experience, as President, effective immediately, as the company moves its previous President into a newly created Chief Technology Officer role.

Fabian succeeds Mathieu Burtnyk, who becomes Chief Technology Officer

Fabian replaces Mathieu Burtnyk, PhD, who shifts to the newly created CTO position. Burtnyk invented the patented closed-loop temperature feedback control algorithm used by the TULSA-PRO platform. He has also led the scientific design and execution of all of the company's clinical studies for the technology, including the ongoing Level 1 post-market CAPTAIN randomized controlled trial.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will hold one-on-one investor meetings at the Lake Street Capital Markets "BIG10" Conference in New York City on September 10, 2026.

The event runs in a one-on-one meeting format only. Profound will not offer a webcast, so investors who want access to management must attend the meetings in person.

Profound Medical sells interventional MRI therapies built around two platforms

The commercial-stage medical device company develops and markets interventional MRI (iMRI) procedures. Its flagship platform, TULSA-PRO, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure to see, ablate and confirm therapy in real time. The approach covers treatment from whole-gland to subtotal, hemi, multifocal and focal ablation.

Toronto – October 12, 2026 -- Profound Medical Corp. expects third-quarter 2026 revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.

Revenue nearly doubles year over year and almost quadruples sequentially

The preliminary, unaudited range implies growth of approximately 85% to 89% from $5.3 million in the third quarter of 2025. Compared with $2.5 million in the second quarter of 2026, revenue is expected to rise approximately 292% to 300%.

The Nasdaq- and TSX-listed company expects gross margin to exceed 70% for the quarter, again above that threshold. Profound attributes the margin to progress in its commercial operations and scale.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has signed a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), giving it wider access to urologists in the U.S. and internationally through a strategic partner in prostate cancer imaging.

The agreement sets a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on how Telix's PSMA-targeting PET imaging agents, Gozellix and Illuccix, complement Profound's MRI-guided TULSA-PRO platform. The companies plan to cover the full prostate care continuum.